Новостная лента

• 

  Cardiol Therapeutics enrolls first patient in Phase II CardiolRx study on recurrent pericarditis

  Proactive Investors

  17 янв 2023 г. в 10:09

  Cardiol Therapeutics Inc (TSX:CRDL, NASDAQ:CRDL) said it has enrolled the first patient in its Phase II study evaluating CardiolRx for the treatment of recurrent pericarditis. The company-sponsored Phase II open-label pilot study is investigating the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis – inflammation of the membrane that surrounds the heart, known as the pericardium.

• 

  Cardiol Therapeutics kicks off a multi-center Phase II pilot study of CardiolRx for the treatment of recurrent pericarditis

  Proactive Investors

  12 дек 2022 г. в 11:59

  Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc revealed that it had initiated a Phase II open-label pilot study to investigate the safety and effectiveness of its lead product candidate CardiolRx in patients with recurrent pericarditis, which refers to inflammation of the pericardium, the membrane or sac that surrounds the heart to hold it in place and help it to work. In addition to standard safety assessments, the Oakville, Ontario-based clinical-stage life sciences company said the study is designed to evaluate improvement in objective measures of disease, and during an extension period, assess the feasibility of a weaning concomitant background therapy including corticosteroids, while taking CardiolRx.

• 

  Cardiol Therapeutics unveils new study data highlighting protective effects of CardiolRx in acute pericarditis

  Proactive Investors

  07 ноя 2022 г. в 09:18

  Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc revealed new study results highlighting the protective effects of CardiolRx in a model of acute pericarditis. The study demonstrated that pharmaceutically manufactured cannabidiol – the active pharmaceutical ingredient in CardiolRx – significantly reduced pericardial effusion and thickening in a pre-clinical model of acute pericarditis, according to a statement.

• 

  Cardiol Therapeutics to prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heart

  Proactive Investors

  25 окт 2022 г. в 09:30

  Cardiol Therapeutics Inc (TSX:CRDL, NASDAQ:CRDL) has said it will prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heart - acute myocarditis and recurrent pericarditis - and announced that its cash runway now extends into 2026. The company also said it will discontinue its LANCER trial, which was designed to investigate the cardioprotective properties of CardiolRx in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease, due to a continuous decline in the number of eligible patients, and a lower than anticipated event rate in the study.

• 

  Cardiol Therapeutics says to prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heart

  Proactive Investors

  25 окт 2022 г. в 07:26

  Cardiol Therapeutics Inc (TSX:CRDL, NASDAQ:CRDL) has said it will prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heart - acute myocarditis and recurrent pericarditis - and announced that its cash runway now extends into 2026. The company also said it will discontinue its LANCER trial, which was designed to investigate the cardioprotective properties of CardiolRx in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease, due to a continuous decline in the number of eligible patients, and a lower than anticipated event rate in the study.